Conde, Diego <br/><br/>
Propafenone versus vernakalant for conversion of recent-onset atrial fibrillation.  [electronic resource] 

 -  Cardiovascular therapeutics  Dec 2013 
 - 377-80 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Comparative Study; Journal Article 
<br/><br/><label>ISSN: </label>1755-5922 
<br/><br/><label>Standard No.: </label>10.1111/1755-5922.12036  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Anisoles--adverse effects<br/>Anti-Arrhythmia Agents--therapeutic use<br/>Atrial Fibrillation--drug therapy<br/>Female<br/>Humans<br/>Length of Stay<br/>Male<br/>Middle Aged<br/>Propafenone--adverse effects<br/>Prospective Studies<br/>Pyrrolidines--adverse effects